Cancer

Primum Health Raises Seed Round Led by FCA Venture Partners and North Coast Ventures

Funding will fuel rapid expansion of the Columbus-based oncology platform, which connects community oncologists with subspecialty experts and real-world insights…

3 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment…

3 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital MarketGRAND CAYMAN,…

3 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is…

3 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company…

3 months ago

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of…

3 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T…

3 months ago

Tiziana to Advance TZLS-501 – Its Fully Human IL-6R Monoclonal Antibody

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it…

3 months ago

Predictive Oncology Announces 1-for-15 Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology…

3 months ago